Xeris Biopharma Holdings
XERS
70 hedge funds and large institutions have $42.9M invested in Xeris Biopharma Holdings in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 31 closing their positions.
328% more call options, than puts
Call options by funds: $5.3M | Put options by funds: $1.24M
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
16.08% less ownership
Funds ownership: 42.42% → 26.34% (-16%)
25% less funds holding
Funds holding: 93 → 70 (-23)
63% less capital invested
Capital invested by funds: $115M → $42.9M (-$71.9M)
74% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.54M |
| 2 |
DAM
Deltec Asset Management
New York
|
+$537K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$506K |
| 4 |
Lazard Asset Management
New York
|
+$399K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$381K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$26.7M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$7.39M |
| 3 |
Renaissance Technologies
New York
|
-$3.18M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$1.22M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.06M |
XERS Hedge Fund Activity: Q3 2021 in Review
70 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2021, worth a combined $42.9M — down 63% from $115M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of XERS and 8 opened new positions — a net loss of 23 holders — while 23 trimmed existing stakes and 24 added.
The largest buyer was Susquehanna International Group, adding an estimated $1.54M. The largest seller was Deerfield Management, exiting entirely with an estimated $26.7M sold.
- 70 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2021, down from 93 in Q2 2021.
- Funds reported $42.9M of Xeris Biopharma Holdings stock for Q3 2021, down 63% quarter-over-quarter.
- 8 funds opened new Xeris Biopharma Holdings positions in Q3 2021 and 31 closed out, a net change of -23 holders.
- The largest Xeris Biopharma Holdings buyer in Q3 2021 was Susquehanna International Group, an estimated $1.54M added.
- The largest Xeris Biopharma Holdings seller in Q3 2021 was Deerfield Management, an estimated $26.7M sold.
Based on aggregated 13F filings for Q3 2021.